The effect of esterification at the 2'-position of desosamine on the antibacterial activity of erythromycin was investigated by determining the bacteriostatic and bactericidal activities of erythromycin and a number of its 2'-esters on S. aureus and relating these activities to the hydrolysis rates of the esters. These studies, together with comparison of the inhibition of protein synthesis in a cell-free system isolated from S. aureus, lead to the conclusion that 2'-esters of erythromycin are inactive until hydrolyzed. Loss of activity appears to result from inability of erythromycin esters to bind to bacterial ribosomes and thus inhibit synthesis of protein.
The effect of esterification at the 2'-position of desosamine on the antibacterial activity of erythromycin was investigated by determining the bacteriostatic and bactericidal activities of erythromycin and a number of its 2'-esters on S. aureus and relating these activities to the hydrolysis rates of the esters. These studies, together with comparison of the inhibition of protein synthesis in a cell-free system isolated from S. aureus, lead to the conclusion that 2'-esters of erythromycin are inactive until hydrolyzed. Loss of activity appears to result from inability of erythromycin esters to bind to bacterial ribosomes and thus inhibit synthesis of protein.
2'-Esters of erythromycin were found by Murphy (5) to possess less antimicrobial activity than the parent compound, erythromycin. Although the 2'-esters of erythromycin are less active than the parent compound, they are not completely inactive, and the question arises whether the low level of activity observed was due to erythromycin formed by ester hydrolysis or whether the 2-esters possess intrinsic antibacterial activity. Kavanagh (1) states that erythromycin esters (for example, 2'-propionyl or 2'-ethyl carbonyl erythromycin) have little if any antibacterial activity until hydrolyzed.
When erythromycin is administered orally in the form of its 2-esters (2'-ethyl succinyl erythromycin or 2'-ethyl carbonyl erythromycin) or as ester salts (erythromycin estolate), the compound is absorbed, distributed in the body, and excreted in large part in the ester form (R. G. Wiegand, et. al. in preparation). Since hydrolysis of the ester is essentially complete under conditions routinely used for analysis of antibacterial activity in serum, the serum concentrations reported in the literature for these dosage forms are a measure of total concentration (base plus ester). This would not be a true measure of the antibacterial activity in the serum in vivo if, indeed, the 2'-esters of erythromycin are inactive. Thus more definitive data on the activity of erythromycin esters was sought.
In this study, several approaches were used to determine the effect of esterification in the 2'-position on the antibacterial activity of erythromycin. First, the inhibition of growth of S. aureus by erythromycin and a number of 2'-esters was determined as a function of time and drug concentration, and the relationships between these determined activities and the hydrolysis rates of the different esters were established. Second, the bactericidal activity of erythromycin and some of its 2'-esters was determined as a function of time.
Erythromycin inhibits bacterial growth by blocking protein synthesis (4, 7) . At saturation, a 1:1 complex between erythromycin and ribosomes is formed (3), and available evidence (8) indicates that binding of erythromycin to ribosomes is a prerequisite for inhibition of protein synthesis. The binding of several 2'-esters of erythromycin to ribosomes was therefore tested and compared with the binding of erythromycin and certain other active derivatives. Propionyl erythromycin (855 p&g per mg) was purchased from the Eli Lilly & Co., Indianapolis, Ind. Acetyl erythromycin (600 ug per mg) and benzoyl erythromycin (about 514 pg per mg) were synthesized by the method of Murphy (5) . Prior to use, the latter two esters were purified by countercurrent distribution by using the system described by Pettinga, et. al. (6) .
MATERIALS AND METHODS

Erythromycin
Erythromycin B, erythromycin C, and N-ethyl erythromycin were all prepared in the Department of Organic Chemistry, Abbott Laboratories.
Hydrolysis studies. Hydrolysis rates were determined in 0.1 M phosphate buffer at pH values of 6.5, 7.0, and 7.5, in Difco Brain Heart Infusion (BHI) broth (37.0 g/liter in deionized water adjusted to pH 6.5 before sterilization for 30 min at 125 C) and in human serum. The procedure was as follows. A known volume, usually 50 ml of buffer, BHI broth, or human serum was warmed in a water bath to 37 C. A known quantity of ester in acetone solution (usually 50 ;liter of a 10 mg/ml of solution) was added to the heated solution, and a 10-ml sample was taken immediately after mixing and placed in a capped test 159 160 TARDREW, MAI tube containing 7 ml of ether held in an ice bath. The sample was extracted immediately by the procedure outlined below.
The solution of ester was shaken at 37 C in the water bath, and, at appropriate intervals (15 min for rapidly hydrolyzing esters, 30 to 60 min for more slowly hydrolyzing esters), samples were withdrawn and extracted immediately. The test tube containing the sample and ether were shaken (120 to 140 cycles per minute) on a reciprocating shaker for 5 min, and the phases were separated by centrifuging in an International model V centrifuge for 5 min. With the aid of a syringe and pipette, the ether was removed and put into separate clean test tubes. A 7 ml portion of ether and 10 ml of phosphate buffer (pH 9.5; 600 g/liter) were added to the test tubes containing the samples, and the extraction procedure was repeated. The ether was then removed and combined with the ether from the first extraction, and the extraction procedure was repeated with 7 ml of ether. A small quantity of anhydrous sodium sulfate was added to the combined ether extract. The ether was decanted into a second clean test tube and evaporated to dryness with an air jet at about 30 C.
Two procedures were used to determine the ratio of ester to base in the extracted samples. In the first of these, the air-dried ether extracts were dissolved in 0.1 ml of Analytical-Reagent (AR) grade acetone. Of this solution, 50 pliters were applied to thin-layer chromatographic plates prepared by applying 30 g of Silica Gel G (E. Merck AG Darmstadt, Germany) in 60 ml of water to a thickness of 0.25 mm and drying at 110 C for 1 hr. An erythromycin base and ester standard was applied to each plate. The chromatograms were developed with a 2:7:1 mixture of diethyl carbinol, ethyl acetate, and dimethyl formamide. In this system the RF of erythromycin is 0.35, whereas the esters fall in the range of Rp 0.65 to 0.75.
After development the plates were removed and dried for 30 min at 75 C in a vacuum oven. While the plates were still hot, they were sprayed with a mixture of arsenomolybdate reagent and 6 N H2SO4 in the ratio of 1:2 (v/v). Erythromycin and its esters are detected as blue spots on a white background.
After the plates had cooled, the ester and base zones were scraped off into clean Pyrex test tubes (20 by 20 mm) to which 0.1 ml of AR grade chloroform was added. Five ml of the arsenomolybdate, 6 N H2SO4 reagent in a ratio of 1:2 was added to each test tube which was then placed in a boiling-water bath for 17 min. After cooling, the tubes were centrifuged at 1,000 X g on an International centrifuge size Z model V for 10 min, and the optical density (OD) was determined at 660 nm with the use of a DU spectrophotometer (Beckman Instruments Inc., Fullerton, Calif.). Per cent ester in the sample was calculated from the equation: % ester = OD ester zone/(OD ester zone + OD base zone) X 100 The arsenomolybdate reagent used in the spray reagent for detection of ester and base on the developed thin-layer chromatographic plates and also in the analytical reagent was prepared as follows. In the second procedure, ester-base ratios were determined bioautographically. Sufficient acetone solution (prepared as described in the thin-layer procedure) to give 200,ug of activity was applied to strips of Eaton Dikeman 613 paper 5/16-inch (0.8 cm) wide. The strips were developed at 28 C by the upflow procedure for 3 hr by using a solvent prepared by dissolving 25 g of AR ammonium chloride and 50 ml of p-dioxane in 850 ml of distilled water, adjusting to a pH of 5.5 with ammonium hydroxide, and diluting to 1 liter. The solvent front was marked after development and the strips were air-dried. Bioautographs were produced by placing the developed strips on a single layer of Streptomycin Assay Agar (Difco) seeded with a known volume of a spore suspension of Bacillus subtilis and incubated overnight at 28 C. The developed bioautographs were photostated, the ratio of the diameters of the ester zone (RF approximately 0.5) to the base zone (RF approximately 0.7) was measured, and the per cent ester was determined from a standard curve. A typical standard curve is shown in Fig. 1 .
Bacteriostatic studies. Bacteriostatic activity of erythromycin and its esters were determined by the following procedure. A 3.0-ml portion of BHI broth (pH 6.5) was inoculated with 0.5 ml of an actively growing subculture (1 to 2 hr) of an 18-hr broth cul- RESULTS AND DISCUSSION To determine if 2'-esters of erythromycin are active it is necessary to first know the rate of ester hydrolysis, since erythromycin base released during the determination of the bactericidal or bacteriostatic activity of the esters will inhibit growth of the test organism.
Hydrolysis rates were determined by direct analysis of ester-base ratios. Determination of the rate of hydrolysis at constant pH in the range 6.5 to 7.5 by titration was not used, because the change in basicity of the ester on hydrolysis results in artificially low rate constants.
In Tables 1 and 2 different esters are listed in order of hydrolysis rates as determined by both thin-layer chromatographic and bioautographic procedures. Esters can be listed in order of in- creasing stability as follows: 2'-ethyl succinyl erythromycin, 2'-acetyl erythromycin, 2'-propionyl erythromycin, 2'-ethyl carbonyl erythromycin, 2'-benzoyl erythromycin.
As Typical inhibition curves obtained when different 2'-esters of erythromycin and erythromycin were compared by the bacteriostatic procedure described are shown in Fig. 2. In Fig. 3 the apparent per cent inhibition after 2 hr of exposure to antibiotic is plotted as a function of concentration. As can be seen from Fig. 2 , apparent inhibition of growth is not complete even at the highest concentration of erythromycin studied (2.5 ug/ml), at which time erythromycin has been shown to be bactericidal (Fig. 4) . This incomplete inhibition probably reflects an increase in absorbance due to increase in the size of the bacterial cells even though cell division has ceased. It is evident from the data in Fig. 2 and 3 that 2'-esters are less active than erythromycin and that the apparent activity decreases in the order: Of S. aureus 209P after 2 hr at 1.0 pg/ml. ,gg/ml. These results are consistent with the hypothesis that 2'-esters of erythromycin are inactive per se and that activity results from erythromycin formed by ester hydrolysis.
In Table 3 , apparent inhibition of S. aureus by different esters at 2 hr and at a concentration of 1.0 jig/ml is compared with the half-times of hydrolysis determined under similar conditions (BHI broth at pH of 6.5 and 37 C). The relative activities of the esters, defined as that concentra- tion of base which will produce the same apparent inhibition in 2 hr as 1.0~g per ml of ester, are also shown in Table 3 . From these data, 2'-ethyl succinyl erythromycin appears to be 10% as active as erythromycin, 2'-propionyl erythromycin 4%, and 2'-ethyl carbonyl erythromycin and 2'-benzoyl erythromycin less than 1%. Under the conditions used in these experiments, 2'-ethyl succinyl erythromycin is approximately 90% and 2'-propionyl erythromycin approximately 50% hydrolyzed after 2 hr. This means that the observed inhibition is due in large part to erythromycin formed by hydrolysis rather than to any intrinsic activity of the 2'-esters. 2'-Benzoyl erythromycin and 2'-ethyl carbonyl erythromycin are only slightly hydrolyzed (approximately 22% and 5%, respectively) under these conditions. The low inhibition observed with 2'-ethyl carbonyl and 2'-benzoyl erythromycin again strongly supports the conclusion that esterification of erythromycin in the 2'-position causes loss of antibacterial activity.
To confirm these conclusions the bactericidal activities of erythromycin and its ethyl succinyl,
propionyl, ethyl carbonyl, and benzoyl esters were determined. Results are summarized in Fig.  4 . As with the bacteriostatic activities, the bactericidal activities of the esters as measured by this technique are a function of the hydrolysis rates of the esters, and these esters appear to possess little if any bactericidal activity until hydrolyzed.
Since the primary action of erythromycin on susceptible organisms is inhibition of protein synthesis (4, 7), the ability of 2'-propionyl erythromycin to inhibit protein synthesis was compared with that of erythromycin in the cell-free system derived from S. aureus (Table 4) . Although it seems that 2'-propionyl erythromycin can inhibit protein synthesis, the inhibition is substantially lower than with erythromycin. However, the protein synthesis assay was performed at 37 C for 30 min in buffer at a pH of 7.5. Again appreciable amounts of 2'-propionyl erythromycin are hydrolyzed under these conditions, suggesting that the inhibition observed with 2'-propionyl erythromycin is due entirely to the erythromycin produced.
Recently, it has been reported that erythromycin forms a 1:1 complex with bacterial ribosomes (3). Also, evidence indicates that binding of erythromycin to ribosomes is a prerequisite for the inhibition of protein synthesis (8) .
Several erythromycin derivatives were tested for their ability to reduce '4C-erythromycin binding to ribosomes at a concentration equal to and at 2.5 and 5 times the concentration of 4C-erythromycin. A correlation between antibacterial activity and inhibition of the 14C-erythromycin binding is clearly shown in Table 5 . Compounds with high antibacterial activity reduce 14C-erythromycin binding significantly, whereas compounds with low antibacterial activity are unable to inhibit 14C-erythromycin binding or inhibit it only slightly. If per cent of displacement of 14C-erythromycin is plotted against relative antibacterial activity (Fig. 5) , it is possible to estimate the relative antibacterial activity of these three esters. By this method, the estimated activities are 60, 35, and 15 ,g/,umole for 2'-acetyl, 2'-propionyl, and 2'-benzoyl erythromycin, respectively.
In summary, then, esterification of erythromycin in the 2' position causes substantial reduction in, and probably complete loss of, antibacterial activity. This loss of activity apparently results from the inability of the 2'-esters, in contrast to erythromycin, to combine with bacterial ribosomes and thus inhibit synthesis of protein by the affected organism. This conclusion has considerable significance in relation to the use of these derivatives of erythromycin in the chemotherapy of bacterial disease.
